WO2001010454A3 - Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infection - Google Patents

Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infection Download PDF

Info

Publication number
WO2001010454A3
WO2001010454A3 PCT/US2000/021462 US0021462W WO0110454A3 WO 2001010454 A3 WO2001010454 A3 WO 2001010454A3 US 0021462 W US0021462 W US 0021462W WO 0110454 A3 WO0110454 A3 WO 0110454A3
Authority
WO
WIPO (PCT)
Prior art keywords
asparaginase
peg
treatment
pharmaceutical composition
hiv infection
Prior art date
Application number
PCT/US2000/021462
Other languages
French (fr)
Other versions
WO2001010454A9 (en
WO2001010454B1 (en
WO2001010454A2 (en
Inventor
Vassilios L Avramis
Lewis Cohen
Original Assignee
Aventis Pharm Prod Inc
Vassilios L Avramis
Lewis Cohen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/370,390 external-priority patent/US6689762B1/en
Application filed by Aventis Pharm Prod Inc, Vassilios L Avramis, Lewis Cohen filed Critical Aventis Pharm Prod Inc
Priority to EP00957306A priority Critical patent/EP1143990A3/en
Priority to CA002346063A priority patent/CA2346063A1/en
Priority to JP2001514970A priority patent/JP2003506409A/en
Priority to AU68944/00A priority patent/AU6894400A/en
Publication of WO2001010454A2 publication Critical patent/WO2001010454A2/en
Publication of WO2001010454A3 publication Critical patent/WO2001010454A3/en
Priority to HK02102802.2A priority patent/HK1041444A1/en
Publication of WO2001010454B1 publication Critical patent/WO2001010454B1/en
Publication of WO2001010454A9 publication Critical patent/WO2001010454A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Abstract

Method of inhibiting or treating Human Immunodeficiency Virus (HIV) infection, comprising administering to a patient in need thereof an effective amount of a pharmaceutically acceptable composition comprising a PEG-ASNase compound or asparaginase, and optionally at least one compound selected from the group consisting of protease inhibitor compounds, ribonucleotide reductase inhibitor compounds and HIV reverse transcriptase inhibitor compounds.
PCT/US2000/021462 1999-08-06 2000-08-07 Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infection WO2001010454A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP00957306A EP1143990A3 (en) 1999-08-06 2000-08-07 Pharmaceutical compostions comprising peg-asparaginase for the treatment of hiv infections
CA002346063A CA2346063A1 (en) 1999-08-06 2000-08-07 Composition and methods for treatment of hiv infection
JP2001514970A JP2003506409A (en) 1999-08-06 2000-08-07 Compositions and methods for treating HIV infection
AU68944/00A AU6894400A (en) 1999-08-06 2000-08-07 Composition and methods for treatment of HIV infection
HK02102802.2A HK1041444A1 (en) 1999-08-06 2002-04-13 Pharmaceutical compositions comprising peg-asparaginase for the treatment of hiv infections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/370,390 1999-08-06
US09/370,390 US6689762B1 (en) 1998-02-09 1999-08-06 Composition and methods for treatment of HIV infection

Publications (4)

Publication Number Publication Date
WO2001010454A2 WO2001010454A2 (en) 2001-02-15
WO2001010454A3 true WO2001010454A3 (en) 2002-01-24
WO2001010454B1 WO2001010454B1 (en) 2002-07-11
WO2001010454A9 WO2001010454A9 (en) 2002-11-07

Family

ID=23459436

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/021462 WO2001010454A2 (en) 1999-08-06 2000-08-07 Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infection

Country Status (7)

Country Link
EP (1) EP1143990A3 (en)
JP (1) JP2003506409A (en)
AU (1) AU6894400A (en)
CA (1) CA2346063A1 (en)
HK (1) HK1041444A1 (en)
WO (1) WO2001010454A2 (en)
ZA (1) ZA200102506B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911460B2 (en) 2001-04-20 2005-06-28 Vion Pharmaceuticals, Inc. Antiviral agents and methods of treating viral infections
WO2005115405A1 (en) * 2004-04-28 2005-12-08 Molecules For Health, Inc. Methods for treating or preventing restenosis and other vascular proliferative disorders
EP2030615A3 (en) 2007-08-13 2009-12-02 ELFORD, Howard L. Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
ES2671478T3 (en) 2012-08-31 2018-06-06 Novartis Ag 2'-ethinyl nucleoside derivatives for the treatment of viral infections
SG11201810704WA (en) * 2016-05-31 2018-12-28 Taiho Pharmaceutical Co Ltd Sulfonamide compound or salt thereof
US10889555B2 (en) 2016-05-31 2021-01-12 Taiho Pharmaceutical Co., Ltd. Sulfonamide compound or salt thereof
MX2020005478A (en) * 2017-11-29 2020-08-27 Taiho Pharmaceutical Co Ltd Sulfonamide compounds and use thereof.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0250335A1 (en) * 1986-06-19 1987-12-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Medicament and therapeutical composition for the treatment of tumours as well as for the treatment of infectious diseases caused by a virus
WO1998056410A1 (en) * 1997-06-09 1998-12-17 Childrens Hospital Los Angeles Utilization of wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence
WO1999039732A1 (en) * 1998-02-09 1999-08-12 Aventis Pharmaceuticals Products Inc. Pharmaceutical compositions comprising peg-asparaginase for the treatment of hiv infections

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0250335A1 (en) * 1986-06-19 1987-12-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Medicament and therapeutical composition for the treatment of tumours as well as for the treatment of infectious diseases caused by a virus
WO1998056410A1 (en) * 1997-06-09 1998-12-17 Childrens Hospital Los Angeles Utilization of wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence
WO1999039732A1 (en) * 1998-02-09 1999-08-12 Aventis Pharmaceuticals Products Inc. Pharmaceutical compositions comprising peg-asparaginase for the treatment of hiv infections

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
GISSELBRECHT C ET AL: "Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy. French-Italian Cooperative Group.", AMERICAN JOURNAL OF MEDICINE, (1993 AUG) 95 (2) 188-96., XP002109062 *
HOLLE L M: "Pegaspargase: an alternative?.", ANNALS OF PHARMACOTHERAPY, (1997 MAY) 31 (5) 616-24. REF: 30, XP002109060 *
LEVIEN T.L. ET AL: "Reviews of Pegaspargase and oral pilocarpine.", HOSPITAL PHARMACY, (1995) 30/1 (54-59)., XP002109061 *
MONFARDINI S. ET AL: "Treatment of acquired immunodeficiency syndrome (AIDS)-related cancer.", CANCER TREATMENT REVIEWS, (1994) 20/2 (149-172)., XP002109063 *
TULPULE ANIL ET AL: "Peg-L-asparaginase has activity in relapsed/refractory AIDS-related lymphomas.", JAIDS JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, vol. 21, no. 1, 1 May 1999 (1999-05-01), Third National AIDS Malignancy Conference;Bethesda, Maryland, USA; May 26-27, 1999, pages A38, XP000990979 *
TULPULE, A. ET AL: "Preliminary results of PEG-L-asparaginase (Oncaspar) in the treatment of relapsed/refractory AIDS-related lymphomas.", BLOOD, (NOV. 15, 1998) VOL. 92, NO. 10 SUPPL. 1 PART 1-2, PP. 240B-241B. MEETING INFO.: 40TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY MIAMI BEACH, FLORIDA, USA DECEMBER 4-8, 1998 THE AMERICAN SOCIETY OF HEAMATOLOGY., XP002109058 *
TULPULE, ANIL ET AL: "Preliminary results of PEG-L-asparaginase (Oncaspar) in the treatment of relapsed/refractory AIDS-related lymphomas.", JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, (APRIL 1, 1998) VOL. 17, NO. 4, PP. A31. MEETING INFO.: SECOND NATIONAL AIDS MALIGNANCY CONFERENCE BETHESDA, MARYLAND, USA APRIL 6-8, 1998 NATIONAL CANCER INSTITUTE., XP002109059 *

Also Published As

Publication number Publication date
HK1041444A1 (en) 2002-07-12
JP2003506409A (en) 2003-02-18
EP1143990A3 (en) 2002-03-27
ZA200102506B (en) 2002-03-27
WO2001010454A9 (en) 2002-11-07
AU6894400A (en) 2001-03-05
CA2346063A1 (en) 2001-02-15
WO2001010454B1 (en) 2002-07-11
EP1143990A2 (en) 2001-10-17
WO2001010454A2 (en) 2001-02-15

Similar Documents

Publication Publication Date Title
UA88270C2 (en) Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes
ATE377011T1 (en) GAMMA-HYDROXY-2-(FLUORALKYLAMINOCARBONYL)-1-PIPERAZINE PENTANAMIDE AS AN HIV PROTEASE INHIBITOR
WO2001032153A3 (en) Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
WO2002056912A3 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
IL143512A (en) Azabicycloalkanes, pharmaceutical compositions comprising same and use thereof for the manufacture of medicaments for the prevention or treatment of infection by immunodeficiency virus
WO2001090121A3 (en) Methods and compositions for treating hepatitis c virus
AU2006252214A1 (en) Methods for treating hepatitis delta virus infection with beta-L-2'-deoxy-nucleosides
GEP20104960B (en) USE OF [D-MeALa]3-[EtVal]4-CYCLOSPORIN FOR THE TREATMENT OF HEPATITIS C INFECTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAID [D-MeAla]3-[EtVal]4-CYCLOSPORIN
DE60022525T2 (en) RAMIPRIL FOR PREVENTING CARDIOVASCULAR PROBLEMS
WO2006044968A3 (en) Combination therapy for treating viral infections
EP0766674A4 (en) New hiv protease inhibitors
ZA991029B (en) Composition and methods for treatment of hiv infections.
PL314984A1 (en) Hiv protease inhibitors
WO2001010387A3 (en) Antiviral therapy use of P-glycoprotein modulators
EP2138175A3 (en) Formulations comprising valsartan for treating diabetes or microalbuminuria
WO2001010454A3 (en) Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infection
HUP0103819A3 (en) Crystalline efavirenz pharmaceutical compositions containing it as active ingredient, and use of efavirenz for making medicament available for inhibitions of reverse transcriptase and for treating hiv infection
WO2000041463A3 (en) Combination of hepatitis b vaccine with antiviral agents
EE9700165A (en) A combination, method, and pharmaceutical composition of compounds for inhibiting HIV protease and HIV reverse transcriptase and for preventing or treating HIV infection, or for treating AIDS or ARC.
AU2003217604A8 (en) Method of treating hiv infection by preventing interaction of cd4 and gp120
AU5158000A (en) Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
WO1997026880A3 (en) Use of a combination of delavirdine and one or more protease inhibitors in hiv-1 infected patients
WO1996000068A3 (en) Combination therapy for hiv infection
WO2004013298A3 (en) 2',3'-dideoxynucleoside analogues for the treatment or prevention of flavivitridae infections
AU2396900A (en) Treatment and prevention of hiv and other viral infections

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000957306

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001/02506

Country of ref document: ZA

Ref document number: 200102506

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2346063

Country of ref document: CA

Ref country code: CA

Ref document number: 2346063

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 514970

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 68944/00

Country of ref document: AU

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2000957306

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: B1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWW Wipo information: withdrawn in national office

Ref document number: 2000957306

Country of ref document: EP